SCHEMBL2286904

SCHEMBL2286904

C=CCOc1cc(OC)c(C(=O)C=Cc2ccc(O)cc2)c(OCC=C)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 1/20 0.63
DPP4 P27487 1/20 0.63
NFKB2 Q00653 1/20 0.63
RELA Q04206 1/20 0.63
FLT3 P36888 1/20 0.61
ABCG2 Q9UNQ0 4/20 0.61
SLC5A1 P13866 1/20 0.61
SLC5A2 P31639 1/20 0.61
TDP1 Q9NUW8 3/20 0.59
TP53 P04637 3/20 0.58
MDM2 Q00987 1/20 0.58
CYP3A4 P08684 3/20 0.55
MAPT P10636 3/20 0.55
KMT2A Q03164 3/20 0.55
KDM4E B2RXH2 2/20 0.55
MEN1 O00255 2/20 0.55
HPGD P15428 2/20 0.55
MCL1 Q07820 1/20 0.55
XDH P47989 1/20 0.54
ATM Q13315 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30383403 1.00 NFKB1 (0.63) NFKB1DPP4NFKB2RELAFLT3
SCHEMBL2286892 1.00 NFKB1 (0.63) NFKB1DPP4NFKB2RELAFLT3
SCHEMBL2284249 0.92 FLT3 (0.73) NFKB1DPP4NFKB2RELAFLT3
SCHEMBL2284259 0.92 FLT3 (0.73) NFKB1DPP4NFKB2RELAFLT3
SCHEMBL2283509 0.91 FLT3 (0.61) NFKB1DPP4NFKB2RELAFLT3
SCHEMBL2283498 0.91 FLT3 (0.61) NFKB1DPP4NFKB2RELAFLT3
SCHEMBL2283524 0.90 FLT3 (0.60) NFKB1DPP4NFKB2RELAFLT3
SCHEMBL2282041 0.90 KDM4E (0.66) NFKB1NFKB2RELAFLT3ABCG2
SCHEMBL2282048 0.90 KDM4E (0.66) NFKB1NFKB2RELAFLT3ABCG2
SCHEMBL2282340 0.90 FLT3 (0.60) NFKB1DPP4NFKB2RELAFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
US-9061984-B2 Compounds related to chalcones and benzothienopyrimidines, their synthesis, and uses to treat diseases UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2015-06-23 US disclosed
US-20110190325-A1 COMPOUNDS, THEIR SYNTHESES, AND THIER USES THE JOHNS HOPKINS UNIVERSITY 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B NFKB1 1669/4885DPP4 4226/4885NFKB2 1728/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 NFKB1 2437/4885DPP4 3670/4885NFKB2 2273/4885
US-20110190325-A1 COMPOUNDS, THEIR SYNTHESES, AND THIER USES TERT, TYMS, NISCH NFKB1 2624/4885DPP4 3127/4885NFKB2 2728/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 NFKB1 2437/4885DPP4 3670/4885NFKB2 2273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.